VRTX Stock Price Today (October 2026) — Vertex Pharmaceuticals Incorporated Analysis & Key Metrics 2026-10-07
Vertex Pharmaceuticals Incorporated (VRTX) is trading at $505.64, up 0.66% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $571.39 (13.0% upside).
- Volatility is low (14.66% annualized), implying relatively contained price movements for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (12.50% YoY) alongside competitive pressures in the Biotechnology space.
VRTX Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Vertex Pharmaceuticals Incorporated - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $122.29B
P/E Ratio
Forward P/E: 24.75
Revenue Growth
Year over Year
Analyst Target
+13.0% upside potential
Key Investor Questions About VRTX
What investors need to know before buying
Based on current market data, VRTX presents a neutral technical setup with looking solid fundamentals.
- Technicals say: Neutral (RSI 37.51)
- Fundamentals say: Looking solid (debt and growth supportive)
VRTX's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for VRTX investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $1.98B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, VRTX stock traded between $400.74 and $560.25 and currently trades in the middle of that range. Big swings are less likely unless a major catalyst emerges.
Volatility & Risk Profile
With 14.66% annualized volatility and β=0.64, the stock exhibits low sensitivity to market moves—making VRTX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now?
Fresh Coverage Puts Maze Therapeutics in Focus Maze Therapeutics (MAZE) moved higher in pre-market trading on 23 September after CIBC began covering the clinical-stage kidney and metabolic disease specialist, with the share reaction unfolding alongside new kidney data from Vertex Pharmaceuticals. Recent trading has been choppy for Maze Therapeutics, with a 1-day share price return that declined 6.69% following a 7-day share price return up 11.82%. The year-to-date share price return is down...
Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know
Vertex Pharmaceuticals (VRTX) closed at $522.38 in the latest trading session, marking a +1.17% move from the prior day.
Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?
VRTX is expanding beyond its CF stronghold with a promising kidney disease pipeline led by povetacicept and inaxaplin.
Lilly’s latest China drug deal; Immunovant’s setback in lupus
Lilly wagered up to $3.35 billion in its fourth China-focused alliance since January 2025. Elsewhere, analysts are now more confident about one of Vertex’s top prospects and an RNA drug succeeded against a rare form of ALS.
CRISPR Therapeutics vs. Vertex Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?
One is burning cash while chasing gene-editing breakthroughs. The other generates billions from a single therapy. Their divergent paths reveal starkly different risk-reward profiles.
Vertex (VRTX) Stock Could Be 24% Undervalued As Kidney Trial Progress Continues
Vertex Pharmaceuticals has ridden a powerful five year share price run while pushing deeper into kidney disease, endocrinology and pain treatments, which puts fresh attention on what investors are really paying for its cash flows today. With the stock near recent highs after a series of clinical and commercial updates, the open question is whether the current market price lines up with the cash the business is expected to generate over time. Over the past 5 years, Vertex Pharmaceuticals has...
Vertex Posts Positive Phase II Data on Kidney Disease Drug
VRTX announces positive AMPLIFIED data for inaxaplin, while completing AMPLITUDE enrollment and targeting interim results in early 2027.
The Surprise That Sent Vertex — And Its Chief Rival — Soaring
Vertex stock popped Tuesday — while shares of rival Maze Therapeutics skyrocketed — on a surprise expansion for their kidney disease drugs.
Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder
Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.
Vertex’s Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
Explore More Analysis for VRTX
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 2, 2026 (after the close, usually)
Frequently Asked Questions
Common investor questions about Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated (VRTX) is currently trading at $505.64. The RSI (14-day) is at 37.5, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $571.39 implies 13.0% upside from current levels. Volatility is low at 14.7% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Vertex Pharmaceuticals Incorporated (VRTX): The trailing P/E ratio is 30.10, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 24.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.90, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 6.50. Price-to-Sales is 10.46. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering VRTX, the consensus price target is $571.39. This represents a 13.0% upside from the current price of $505.64. The range spans from a low target of $350.00 to a high target of $672.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Vertex Pharmaceuticals Incorporated (VRTX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Vertex Pharmaceuticals Incorporated (VRTX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Vertex Pharmaceuticals Incorporated's (VRTX) current debt and financial health profile: Total debt stands at $1.98B. The debt-to-equity ratio is 0.10x, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 3.19, indicating strong short-term liquidity. The quick ratio is 2.54. The company holds $7.85B in cash and equivalents. Free cash flow is positive at $2.63B, providing a cushion for debt servicing and shareholder returns.